Appian Corporation NASDAQ: APPN, long recognized for its process automation software, has quietly developed one of the most practical AI platforms in enterprise technology, and investors have only recently begun to take notice.

Merck & Co., Inc. ( MRK ) M&A Call November 17, 2025 8:00 AM EST Company Participants Peter Dannenbaum - Vice President of Investor Relations Robert Davis - Chairman, President & CEO Dean Li - Executive VP & President of Merck Research Laboratories Chirfi Guindo - Senior VP & Chief Marketing Officer of Human Health Caroline Litchfield - Executive VP & CFO Conference Call Participants Carter Gould - Cantor Fitzgerald & Co., Research Division James Shin - Deutsche Bank AG, Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Alexandria Hammond …

Shares of Ford Motor Company ( NYSE: F ) gained 9.65% over the past month after gaining 2.32% the month prior.

abrdn Healthcare Investors offers a discounted entry into the healthcare sector, with a strong tilt toward biotechnology exposure and active management. HQH has recently outperformed both the S&P 500 and biotech benchmarks, driven by relatively smaller-cap or lesser-known holdings like QURE, ALNY, ARGX, and CYTK. HQH suits more aggressive investors comfortable with volatility over the long term, or can appeal to tactical exposure to a recovering biotech sector via a discounted CEF structure.

U.S. broadcaster Sinclair on Monday disclosed an 8.2% stake in smaller rival E.W. Scripps and said it has been in talks for months about a deal that would combine the companies.

Global energy outlooks from OPEC, IEA, and EIA reveal a clear shift toward oil oversupply through 2025-2026, driven by strong non-OPEC production and slower demand concentrated in Asia. This analysis highlights key areas of agreement across all three agencies and what it means for crude pricing, market power, and future

ARLINGTON, Va., Nov. 17, 2025 (GLOBE NEWSWIRE) -- OBOOK Holdings Inc. (NASDAQ: OWLS) (the "Company" or "OwlTing"), a blockchain technology company operating as the OwlTing Group, today shared updated indicators of accelerating enterprise adoption across stablecoin-based settlement and tokenized financial infrastructure, as global companies shift from pilot exploration to real production integration.

Digital payments firm Ant International has launched a blockchain-centered partnership with banking giant UBS. The collaboration, announced Monday (Nov. 17), will see the companies explore the use of blockchain-based tokenized deposits to support Ant International's global payments settlement and liquidity management.

Kyndryl Holdings, Inc. has experienced a significant 37% decline in its stock price since June 30, 2025. Key focus is on the factors contributing to KD's sharp stock drop. The investment thesis evaluates KD's outlook and the potential for a recovery after the recent plunge.

The Zacks Medical products industry sees steady demand, but macro headwinds keep growth under pressure in 2025. BSX, PODD, BLFS and ALUR reflect the favorable fundamentals.

LOS ANGELES, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Cytokinetics, Incorporated, (“Cytokinetics” or the "Company") (NASDAQ: CYTK) investors of a class action on behalf of investors that bought securities between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). Cytokinetics investors have until November 17, 2025 to file a lead plaintiff motion.

LOS ANGELES, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against KBR, Inc. (“KBR” or “the Company”) (NYSE: KBR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 6, 2025 and June 19, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before November 18, 2025.

Novo Nordisk (NYSE: NVO) has announced sweeping price cuts for its blockbuster GLP-1 drugs, Wegovy and Ozempic, offering patients access to the lowest doses for just $199/month. New cash-paying patients will be able to access its anti-obesity treatments at that price for the first two months, the pharmaceutical behemoth confirmed in a press release today.

U.S. oil and natural gas drilling activity has continued to decline even as production reaches record highs, the U.S. Energy Information Administration (EIA) said on Monday.

CLS' rising earnings estimates and accelerating AI-driven demand spotlight its expanding role in high-value tech infrastructure.

Beyond analysts' top-and-bottom-line estimates for Valvoline (VVV), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.

Evaluate the expected performance of Maximus (MMS) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Evaluate Onto Innovation's (ONTO) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Besides Wall Street's top-and-bottom-line estimates for Veeva (VEEV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended October 2025.

Arbe Robotics Ltd. ( ARBE ) Q3 2025 Earnings Call November 17, 2025 8:30 AM EST Company Participants Jacob Marenko - Co-Founder, CEO & Director Karine Pinto-Flomenboim - Chief Financial Officer Conference Call Participants Kenny Green Sujeeva De Silva - ROTH Capital Partners, LLC, Research Division George Gianarikas - Canaccord Genuity Corp., Research Division Presentation Operator Good day, everyone, and welcome to the Arbe Robotics Third Quarter 2025 Results Conference Call.